Vilela Verônica Silva, da Silva Bruno Rangel Antunes, da Costa Cláudia Henrique, Lopes Agnaldo José, Levy Roger Abramino, Rufino Rogério
State University of Rio de Janeiro, Rio de Janeiro, Brazil.
BMC Res Notes. 2018 Dec 10;11(1):874. doi: 10.1186/s13104-018-3994-1.
To investigate the effect of rituximab on microcirculation in long-term SSc.
Four patients with diffuse SSc over 3 years of disease received rituximab cycles of two 1-g infusions every 6 months for 2 years. Videocapillaroscopy was performed at baseline, 12 months, and 24 months and semi-quantitative scoring of videocapillaroscopy abnormalities was performed and the microangiopathy evolution score (MES: range 0-9) was calculated. The mean disease duration was 5 years (range 3-15). On videocapillaroscopy, giant capillaries and hemorrhages remained stable from baseline to 24 months. Capillary loss, abnormally-shaped capillaries, and MES stabilized at 12 months and increased by 24.5% and 28% at 24 months. Rituximab improves microcirculation in long-term SSc. Stabilization and reduced progression of microcirculation abnormalities were achieved at 12 and 24 months, respectively.
研究利妥昔单抗对长期系统性硬化症（SSc）微循环的影响。
4例病程超过3年的弥漫性SSc患者接受利妥昔单抗治疗，每6个月静脉输注2次，每次1 g，共2年。在基线、12个月和24个月时进行视频毛细血管镜检查，并对视频毛细血管镜异常进行半定量评分，计算微血管病变进展评分（MES：范围0 - 9）。平均病程为5年（范围3 - 15年）。在视频毛细血管镜检查中，从基线到24个月，巨大毛细血管和出血情况保持稳定。毛细血管丢失、畸形毛细血管和MES在12个月时稳定，在24个月时分别增加了24.5%和28%。利妥昔单抗可改善长期SSc患者的微循环。在12个月和24个月时分别实现了微循环异常的稳定和进展减缓。
